
MEDIA RELEASE

Market entry of Ypsomate® autoinjector for Teribone™ in Japan

Burgdorf, 12.12.2019, 7.00 a.m. – Terumo Corporation (Terumo), a leading global manufacturer and distributor of medical devices, will fill its PLAJECT™ syringe with the drug Teribone™ and assemble it with the Ypsomate® prefilled autoinjector from Ypsomed. Teribone™ is a Teriparatide for the treatment of osteoporosis. The drug was developed by Asahi Kasei Pharma (AKP) and is being launched in Japan.

The pre-filled Teribone™ autoinjector is based on Ypsomed's Ypsomate® platform and is designed for subcutaneous injection of liquid drugs. Terumo assembles the Ypsomate® with its proprietary PLAJECT™ syringe for administration of the drug. AKP received market approval for Teribone™ in September 2019 and is launching the drug in Japan in December 2019.

Teribone™ is indicated for the treatment of patients living with Osteoporosis. Osteoporosis is a condition in which the bones become weaker and more fragile. According to the World Health Organisation (WHO), around 200 million people live with Osteoporosis worldwide. To date, Teribone™ has been available in a lyophilized vial formulation, and administration has taken place in the doctor's office. With the launch of Teribone™ in Ypsomed's pre-filled 2-step Ypsomate® autoinjector, patients now have the opportunity to administer the drug themselves at home twice a week, if the treating physician recommends it.

“Ypsomed and Terumo have worked closely together to enhance the value of Teribone™. With the combination of the Ypsomate® autoinjector and PLAJECT™, we are able to provide a new treatment option to patients”, says Tetsuya Kumei, Division President of the Alliance Division, General Hospital Company of Terumo Corporation.

“The Teribone™ autoinjector is already the second commercial market entry with Terumo. We see a growing need for easy-to-use injection devices for home use to increase quality of life, patient adherence and thus reduce healthcare costs”, comments Ulrike Bauer, Senior Vice President Ypsomed Delivery Systems.

For further information, please contact Thomas Kutt, Head of Investor Relations at Ypsomed Holding AG, at the telephone number +41 34 424 35 55 or by e-mail (thomas.kutt@ypsomed.com).

About the Ypsomed Group

The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife™ Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1'700 employees. Additional information is available under www.ypsomed.com.

About Terumo Corporation

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers, with approximately US\$ 6 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices, including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician-office use. Terumo contributes to society by providing valued products and services to the healthcare market, and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange and is a component of the Nikkei 225, Japan's leading stock index.